Inhibikase Therapeautics has received FDA approval to begin a Phase II trial of a compound called IkT-001. This compound is intended to clear the body of JC virus, which is the virus that causes PML. PML is the serious brain infection which has been seen in patients on the MS medication called Tysabri. This study is primarily a safety and dosing study in a small number of patients who are receiving Tysabri.
Although the IMSMP is not participating in this small study at this time, we...
moreDr. James Stark presented the following article at Journal Club this week:
Daclizumab in Active Relapsing Multiple Sclerosis (CHOICE study): A phase 2, randomized, double-blind, placebo-controlled, add-on trial with IFN-beta.
The article presents the results of the phase 2 daclizumab therapy trial. Daclizumab is a monoclonal antibody against a specific part of an immune cell. It is administered by subcutaneous injection once a month. The results showed that patients treated...
moreWe are very pleased to report that Rebecca, a nurse at the IMSMP for several years, has completed her Nurse Practitioner training! Rebecca continued her exemplary work here while going to school, which is an impressive feet on its own. In her new role, Rebecca will work closely with Dr. Sadiq, as well as provide general medical services to employees. She will also join the team at Roosevelt Hospital, rounding on inpatients and participating at clinic.
We are pleased to announce that construction has resumed on the first part of our expansion! MS Imaging of New York will consist of two 3-tesla MRI machines, which will provide exceptional quality images just steps away from your physician's office. Patients can choose to have their MRI right before their doctor's visit so that they will no longer have to wait to review the images with their physician. Furthermore, MRI's may be incorporated into emergency visits if necessary to expedite...
moreCongratulations to our employee of the month, Jennifer Norman! Jennifer has worked tirelessly as our comptroller to secure funding for expansion and to manage the human resources needs of our ever-growing staff. Moreover, as a first for our organization, Jennifer deferred the honor to recognize her colleague, Umar Sadiq, for all of his work.
Congratulations to both of them!
A stem cell trial in the United Kingdom has just received funding to initiate a phase II trial. This study will treat relapsing-remitting patients with autologous, mesenchymal stem cells administered intravenously. This study is similar to the MSRCNY stem cell proposal, except that, in the MSRCNY planned trial, we will be using neural progenitor cells which are derived from mesenchymal stem cells and the cells would be administered intrathecally (directly into the spinal fluid). We eagerly...
moreDr. Andrew Sylvester presented the following article at Journal Club this week: “Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS” by Kowarik et al in Neurology (2011). The discussion focused on the effect of fingolimod on various immune cell types in the brain and cerebrospinal fluid.
We are saddened to report that Amber Peskin, a valued nurse here for over three years, will be leaving the practice in mid-August. As some of you know, Amber is a new mom and wanted to relocate back to her hometown of New Orleans to be closer to her family. We all wish Amber the best and will miss her very much.
Dr. Subramaniam Sriram, from Vanderbilt University, spoke at Grand Rounds this week. His topic was the role of the innate immune system in the development and pathogenesis of MS and he spoke a good deal about his research on nitric oxide. Following his presentation, we discussed how Methotrexate modulates nitric oxide pathways and may be an additional mechanism of its benefit in progressive forms of MS. We will be supplying Dr. Sriram with frozen CSF samples of patients before and after...
moreWe are very pleased to announce that the IMSMP/MSRCNY has had eight posters accepted at this year’s ECTRIMS conference. ECTRIMS is the European Committee for Treatment and Research in Multiple Sclerosis and this year’s meeting will be in Amsterdam in October. Dr. Sadiq and several laboratory personnel will be in attendance. http://www.ectrims.eu/
Because you deserve only the best in MS healthcare. Experience the difference.
Join our mailing list today! Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.
* We don’t share your information with anyone.
